Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half

Author: Benzinga Newsdesk | February 19, 2025 08:03am

2025 Financial Guidance

To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:

Total Revenue Growth117% to 24%
Galafold Revenue Growth110% to 15%
Pombiliti + Opfolda Growth165% to 85%
Gross MarginMid 80%
Non-GAAP Operating Expenses4$350M to $370M
GAAP Net IncomePositive during H2 2025


 

Posted In: FOLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist